Effect of l-ornithine-l-aspartate therapy on the hyperammonemia level and results of the number connection test of patients suffering from nonalcoholic fatty liver disease
https://doi.org/10.31146/1682-8658-ecg-169-9-80-84
Abstract
The aim was to study the hyperammonemia level and the duration of implementation of the number connection test (NCT) for patients with nonalcoholic fatty liver disease (NAFLD) in the pre-cirrhosis stage, including effect of the oral administration of L-ornithine-L-aspartate (LOLA) on these indices, and NCT correlation with body chemistry values. Material and methods: the research covered 103 patients with NAFLD to study the hyperammonemia level and other relevant blood chemistry values; we performed NCT before and after the LOLA treatment. The aim was to study the hyperammonemia level and the duration of implementation of the number connection test (NCT) for patients with nonalcoholic fatty liver disease (NAFLD) in the pre-cirrhosis stage, including effect of the oral administration of L-ornithine-L-aspartate (LOLA) on these indices, and NCT correlation with body chemistry values. Material and methods: the research covered 103 patients with NAFLD to study the hyperammonemia level and other relevant blood chemistry values; we performed NCT before and after the LOLA treatment.
About the Authors
E. A. Kizova
City Clinical Hospital № 13 of Avtozavodsky region of Nizhny Novgorod
Russian Federation
Elena A. Kizova, Head of the Gastroenterology Department, Ph. D.
Russian Federation
Elena A. Kizova, Head of the Gastroenterology Department, Ph. D.
Yu. P. Potekhina
Privolzhsky research medical university
Russian Federation
Yuliya P. Potekhina, Department of Normal Physiology n. a. N. Yu. Belenkov, Professor, D. Sci.
Russian Federation
Yuliya P. Potekhina, Department of Normal Physiology n. a. N. Yu. Belenkov, Professor, D. Sci.
References
1. Levitt D.G., Levitt M. D. A model of blood- ammonia homeostasis based on a quantitative analysis of nitrogen metabolism in the multiple organs involved in the production, catabolism, and excretion of ammoniain in humans. Clin Exp Gastroenterol. 2018, № 11, pp. 193–215.
2. Damink S.W., Jalan R., Redhead D. N., et al. Interorgan ammonia and amino- acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology. 2002, Vol. 36, № 5, pp. 1163–1171.
3. Plotnikova E. Yu., Sukhikh A. S. Different types of hyperammonemia in clinical practice. Meditsinsky sovet (Medical Council). Gastroenterology. 2018, №14, pp. 34–42. (in Russ.)
4. Ageyeva Ye. A., Alekseyenko S. A. Application of the oral “L-ornithine-L-aspartate” at hyperammoniemia at chronic liver diseases at precirrhotic stage. Clinical prospects of gastroenterology, gepatology. 2015, №6, pp. 24–26. (In Russ.)
5. Jalan R., DeChiara F., Balasubramaniyan V., et al. Ammonia produces pathological changes in human hepatic stellate cell sand is target for therapy of portal hypertension. J. Hepatology. 2016, Vol.64, № 4, pp. 823–833.
6. Vilstrup H., Amodio P., Bajaj J., et al. Hepatic encephalopathy in chronic liver disease // 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the Europe an Association for the Study of the Liver. Hepatology. 2014, № 60, pp. 715–735.
7. Bajaj J. S. Minimal hepatic encephalopathy matters in daily life //World J Gastroenterol. 2008, № 14, pp. 3609–3615.
8. Weissenborn K., Ennen J. C., Schomerus H., et al. Neuropsychological characterization of hepatic encephalopathy. J Hepatol. 2001, № 34, pp. 768–773.
9. Wuensch T.; Ruether D. F., Zöllner C., et al. Performance characterization of a novel electronic number connection test to detect minimal hepatic encephalopathy in cirrhotic patients. European Journal of Gastroenterology & Hepatology. 2017, Vol. 29, № 4, pp. 456–463.
10. Felipo V, Urios A, Montesinos E, et al. Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. Metab Brain Dis. 2012, Vol. 27, № 1, pp. 51–58.
11. Rebrova O. Yu. Statistical analysis of medical data. Application of the STATISTICA application package; scientific and educational edition. M.: MediaSfera; 2002: 312 p. (In Russ.).
12. Drapkina O. M., Ivashkin V. T. Epidemiologic features of non-alcoholic fatty liver diseases in Russia (Results of open multicenter prospective observational study DIREGL 01903). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014, Vol. 24, №4, pp. 32–38. (In Russ.)
13. Hamaguchi M, KojimaT, Takeda N, et al. Nonalcoholic fatty liver diseaseis anovel predictor of cardiovascular disease. World J Gastroenterol. 2007, № 13, pp. 1579–1584.
14. Ramilli S, Pretolani S, Muscari A, et al. Carotid lesions in out patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2009, Vol. 15, № 38, pp. 4770–4774.
15. Gryungrayff K., Lambert-Baumann Yo. Efficacy of L-ornithine-L-aspartate granules in the treatment of chronic liver diseases. Modern gastroenterology. 2008, № 2, pp. 59–67. (In Russ.)
Review
For citations:
Kizova E.A., Potekhina Yu.P. Effect of l-ornithine-l-aspartate therapy on the hyperammonemia level and results of the number connection test of patients suffering from nonalcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2019;(9):80-84. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-169-9-80-84
Views:
534
Email this article 